Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Non-Current Assets (2022 - 2025)

Zentalis Pharmaceuticals has reported Other Non-Current Assets over the past 4 years, most recently at $2.6 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $2.6 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $2.6 million (changed 0.0% YoY), and the annual figure for FY2025 was $2.6 million, changed 0.0%.
  • Other Non-Current Assets for Q4 2025 was $2.6 million at Zentalis Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for ZNTL hit a ceiling of $2.9 million in Q1 2022 and a floor of $2.6 million in Q4 2024.
  • Median Other Non-Current Assets over the past 4 years was $2.6 million (2022), compared with a mean of $2.6 million.
  • Peak annual rise in Other Non-Current Assets hit 2.06% in 2023, while the deepest fall reached 8.47% in 2023.
  • Zentalis Pharmaceuticals' Other Non-Current Assets stood at $2.6 million in 2022, then grew by 2.06% to $2.7 million in 2023, then decreased by 3.02% to $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025.
  • The last three reported values for Other Non-Current Assets were $2.6 million (Q4 2025), $2.6 million (Q3 2025), and $2.6 million (Q2 2025) per Business Quant data.